Eli Lilly has seen positive results from a phase 3 trial of Orforglipron, the first-ever GLP-1 pill for weight loss and type ...

Eli Lilly and Co., the maker of Zepbound and Mounjaro, announced a successful Phase 3 trial for a once-daily GLP-1 pill for ...

Tirzepatide was approved in November 2023 by the US Food and Drug Administration (FDA) (Zepbound) and in the EU in June 2024 ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 ...

The once-daily pill, currently under investigation, is being studied for adults with type 2 diabetes who are not on any ...

Eli Lilly said clinical results of its GLP-1 in pill form showed safety and efficacy data similar to blockbuster injectable ...

Eli Lilly reported promising results from a study of its experimental oral drug that could rival popular injections to treat ...

A new weight-loss pill taken daily could compete with injections like Ozempic, research suggests. Patients, who all were ...

Explore medication options for kidney disease and potential side effects. Learn the best treatment options to slow ...